Clinical Research Details Clinical Research Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Study Description This study will test the following experimental drugs: an injectable named semaglutide (SEMA) and a fixed-dose combination tablet named cilofexor/firsocostat (CILO/FIR) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a more severe form of nonalcoholic fatty liver disease in which the liver becomes fatty and inflamed and liver cells become injured. Scarring of the liver (fibrosis) may also occur. Fixed-dose combination means that two experimental drugs are in one tablet and the amount of each drug does not change. Inclusion/Exclusion Criteria Men and nonpregnant, nonlactating women between 18 and 80 years of age, inclusive, with compensated cirrhosis due to NASH, as determined by liver biopsy. Investigators Maged P. Ghali, M.D. Medicine